Lupin plans to launch 25 products in the US in FY18

13 Feb 2017 Evaluate

Lupin is planning to launch around 25 products in the US in next finance year. The drug major’s focus remains on the speciality drugs business in the US.

The Mumbai-based drug firm launched four products in the US market during the third quarter ended December 31. It received 11 approvals from the USFDA during the period. It now has a portfolio of 128 generic products in the US market.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2114.10 33.75 (1.62%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×